Other substances

Micafungin

An echinocandin antifungal.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

Micafungin is a semi-synthetic echinocandin. It noncompetitively inhibits the fungal 1,3-beta-D-glucan synthase and thus blocks the fungal cell wall synthesis. Destabilization of the cell wall leads to fungal cell death (NCIt).

Micafungin on DrugBank
Micafungin on PubChem
Micafungin on Wikipedia


Marketed as

MYCAMINE

 

Structure image - Micafungin

CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O

Supporting references

Link Tested on Impact factor Notes Publication date
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
3CLpro Small molecule Enzyme assay In vitro In silico 		in silico; in vitro enzyme assay

Partialy inhibits (IC50 of 47.6 µM; 57% inhibition at 50 µM) the SARS-CoV-2 3C-like protease in vitro.

 Jan/20/2021

AI-suggested references

Link Publication date
In silico analysis of echinocandins binding to the main proteases of coronaviruses PEDV (3CLpro) and SARS-CoV-2 (Mpro).
Jul/01/2021
Export (.csv)